Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir + Elbasvir in Japanese Patients with Chronic HCV GT1
NCT02203149Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of grazoprevir, elbasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Aug 2014; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02203149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203149.